Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000701339 | SCV000830136 | likely benign | Developmental and epileptic encephalopathy, 14; Autosomal dominant nocturnal frontal lobe epilepsy 5 | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001538972 | SCV001756694 | likely benign | not provided | 2021-06-01 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge |
New York Genome Center | RCV001839019 | SCV002098988 | uncertain significance | Developmental and epileptic encephalopathy, 14 | 2021-03-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004026553 | SCV004893018 | uncertain significance | Inborn genetic diseases | 2023-10-28 | criteria provided, single submitter | clinical testing | The c.32G>A (p.G11E) alteration is located in exon 1 (coding exon 1) of the KCNT1 gene. This alteration results from a G to A substitution at nucleotide position 32, causing the glycine (G) at amino acid position 11 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome |
RCV000701339 | SCV004228975 | not provided | Developmental and epileptic encephalopathy, 14; Autosomal dominant nocturnal frontal lobe epilepsy 5 | no assertion provided | phenotyping only | Variant interpreted as Likely benign and reported on 03-06-2020 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. |